<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834067</url>
  </required_header>
  <id_info>
    <org_study_id>B036544</org_study_id>
    <nct_id>NCT00834067</nct_id>
  </id_info>
  <brief_title>Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative bioavailability of moexipril HCl/
      hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals
      USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking
      subjects under non-fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexipril.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexipril.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexipril.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Hydrochlorothiazide.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Hydrochlorothiazide.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Hydrochlorothiazide.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexiprilat.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexiprilat.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexiprilat.</measure>
    <time_frame>Blood samples collected over a 192 hour period.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moexipril HCl/hydrochlorothiazide 15/25 mg tablets</intervention_name>
    <description>1 x 15/25 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UNIRETIC® 15/25 mg tablets</intervention_name>
    <description>1 x 15/25 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects selected for this study will be non-smokers at least 18 years of age.

          -  Subjects will have a BMI index (body mass index) of 30 or less.

        Exclusion Criteria:

          -  Subjects with a history of chronic alcohol consumption (during past 2 years), drug
             addiction, or serious gastrointestinal, renal, hepatic, tuberculosis, epilepsy, asthma
             (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for this
             study.

          -  Subjects whose clinical laboratory test values are greater than 20% outside the normal
             range may be retested. If the clinical values are outside the range on retesting, the
             subject will not be eligible to participate in the study unless the clinical
             investigator deems the result not to be significant.

          -  Subjects who have a history of allergic responses to the class of drug being tested
             should be excluded from the study.

          -  All subjects will have urine samples assayed for the presence of abuse as part of the
             clinical laboratory screening procedures and ath check-in each study period. Subjects
             found to have urine concentrations of any of the tested drug will not be allowed to
             participate.

          -  Subjects should not have donated blood and/or plasma for at least thirty (30) days
             prior to the first dosing of the study.

          -  Subjects who have taken an investigational drug within thirty (30) days prior to the
             first dosing of the study will not be allowed to participate.

          -  Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant
             during the study will not be allowed to participate. Female subjects of child bearing
             potential must either abstain from sexual intercourse or use a reliable barrier method
             (e.g. condom, IUD) of contraception during the course of the study (first dosing until
             last blood collection) or they will not be allowed to participate. Subjects who have
             used implanted or injected hormonal contraceptives anytime during the 180 days prior
             to study dosing or oral hormonal contraceptives with in 14 days of dosing will not be
             allowed to participate.

          -  All female subjects will be screened for pregnancy at check-in each study period.
             Subjects with positive or inconclusive results will be withdrawn from the study.

          -  Subjects who use tobacco in any form will not be eligible to participate in the study.
             Three months abstinence is required.

          -  Subjects who do not tolerate venipuncture will not be allowed to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irwin Plisco, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gateway Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gateway Medical Research, Inc.</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioassay Laboratory, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>July 2, 2009</results_first_submitted>
  <results_first_submitted_qc>July 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moexipril</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test (Moexipril HCl/HCTZ) First</title>
          <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in first period followed by 15/25 mg Uniretic® Tablets reference product dosed in the second period.</description>
        </group>
        <group group_id="P2">
          <title>Reference (Uniretic®) First</title>
          <description>15/25 mg Uniretic® Tablets reference product dosed in first period followed by 15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout of 21 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test (Moexipril HCl/HCTZ) First</title>
          <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in first period followed by 15/25 mg Uniretic® Tablets reference product dosed in the second period.</description>
        </group>
        <group group_id="B2">
          <title>Reference (Uniretic®) First</title>
          <description>15/25 mg Uniretic® Tablets reference product dosed in first period followed by 15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in the second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexipril.</title>
        <description>Bioequivalence based on Cmax.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexipril.</title>
          <description>Bioequivalence based on Cmax.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.487" spread="6.706"/>
                    <measurement group_id="O2" value="14.885" spread="6.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>96.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>90.1</ci_lower_limit>
            <ci_upper_limit>104</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexipril.</title>
        <description>Bioequivalence based on AUC0-t.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexipril.</title>
          <description>Bioequivalence based on AUC0-t.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.412" spread="41.756"/>
                    <measurement group_id="O2" value="34.917" spread="47.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>104</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.9</ci_lower_limit>
            <ci_upper_limit>108</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexipril.</title>
        <description>Bioequivalence based on AUC0-inf.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexipril.</title>
          <description>Bioequivalence based on AUC0-inf.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.651" spread="43.262"/>
                    <measurement group_id="O2" value="35.74" spread="47.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>103</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.7</ci_lower_limit>
            <ci_upper_limit>107</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Hydrochlorothiazide.</title>
        <description>Bioequivalence based on Cmax.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Hydrochlorothiazide.</title>
          <description>Bioequivalence based on Cmax.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.225" spread="42.664"/>
                    <measurement group_id="O2" value="148.39" spread="39.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Hydrochlorothiazide.</title>
        <description>Bioequivalence based on AUC0-t.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Hydrochlorothiazide.</title>
          <description>Bioequivalence based on AUC0-t.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1105.63" spread="260.669"/>
                    <measurement group_id="O2" value="1100.5" spread="271.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.1</ci_lower_limit>
            <ci_upper_limit>102</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Hydrochlorothiazide.</title>
        <description>Bioequivalence based on AUC0-inf.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Hydrochlorothiazide.</title>
          <description>Bioequivalence based on AUC0-inf.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1115.905" spread="259.765"/>
                    <measurement group_id="O2" value="1108.329" spread="271.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.4</ci_lower_limit>
            <ci_upper_limit>103</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexiprilat.</title>
        <description>Informational comparison of Cmax values for the metabolite Moexiprilat.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) of Moexiprilat.</title>
          <description>Informational comparison of Cmax values for the metabolite Moexiprilat.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.512" spread="3.241"/>
                    <measurement group_id="O2" value="5.13" spread="2.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>107</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.8</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexiprilat.</title>
        <description>Informational comparison of AUC0-t values for the metabolite Moexiprilat.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) of Moexiprilat.</title>
          <description>Informational comparison of AUC0-t values for the metabolite Moexiprilat.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.654" spread="61.545"/>
                    <measurement group_id="O2" value="214.286" spread="69.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>102</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexiprilat.</title>
        <description>Informational comparison of AUC0-inf values for the metabolite Moexiprilat.</description>
        <time_frame>Blood samples collected over a 192 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Moexipril HCl/HCTZ)</title>
            <description>15/25 mg Moexipril HCl/Hydrochlorothiazide Tablets test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Uniretic®)</title>
            <description>15/25 mg Uniretic® Tablets reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) of Moexiprilat.</title>
          <description>Informational comparison of AUC0-inf values for the metabolite Moexiprilat.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376.814" spread="144.282"/>
                    <measurement group_id="O2" value="379.994" spread="184.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>103</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.1</ci_lower_limit>
            <ci_upper_limit>108</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals, USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

